Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 315 participants.

Also called NCT04135287

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 315 participants (planned count) (from the registry)
Sponsor
Dasman Diabetes Institute (from the registry)
Registry
  • NCT NCT04135287
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Kuwait (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04135287. Allocation not applicable; no masking; primary purpose treatment. Start 2020-03-01 (actual); primary completion 2023-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
GLP-1 receptor agonist
Lead sponsor
Dasman Diabetes Institute (class: other)

Record details

Record id
cardio:ct-nct04135287
Content hash
fbea3c5c87ac8e14b15ea3efe5d95a77fba34de7d6db3038321f97ed889d66a1